The immuno oncology assays market is no longer a niche laboratory concern — it has become a cornerstone of modern cancer care. With global cancer incidence climbing and immunotherapy reshaping treatment protocols, the tools used to measure immune responses are now central to how clinicians decide who gets which therapy and when.
The Business Research Company’s Immuno Oncology Assays Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
As cancer research accelerates and personalized treatment strategies gain ground, the immuno oncology assays market is expanding at a remarkable clip. Advances in immunotherapy and biomarker technologies are opening new doors for researchers and healthcare providers alike, making this one of the most closely watched segments in the life sciences space.
Also worth a look: Mitolyn, Built Around the Purple Peel Exploit, has been Launched, Designed to Enhance Mitochondrial Health & Manage Weight and Out Today: “My Favorite Things” by Award-winning Vocalist Nicole Henry.
Market size and growth outlook
The sector has seen substantial momentum in recent years. Valued at $4.88 billion in 2025, the market is projected to reach $5.52 billion in 2026 — a compound annual growth rate (CAGR) of 13.1%. That trajectory is expected to continue, with forecasts pointing to $8.9 billion by 2030 at a CAGR of 12.7%. Drivers include the rising global incidence of cancer, increased investment in immunotherapy research, broader adoption of biomarker-driven diagnostics, and the growing role of personalized medicine. A surge in clinical oncology research has also added fuel to the fire.
Download a free sample of the immuno oncology assays market report:
https://www.thebusinessresearchcompany.com/sample_request?id=86621071&type=smp&name=Immuno%20Oncology%20Assays%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
What’s driving the growth
A key contributor is the rising demand for advanced immune profiling assays, which give clinicians a detailed view of a patient’s immune response and support more effective treatment planning. Precision oncology — tailoring therapies to an individual’s tumor profile — is also gaining wider acceptance, while the development of novel immunotherapies continues to push the field forward. Predictive biomarkers are increasingly used to guide treatment decisions, and collaborations between pharmaceutical companies and research institutions are accelerating innovation and adoption across the board.
View the full immuno oncology assays market report:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-assays-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Trends shaping the future
Multiplex immuno oncology assays — which allow simultaneous analysis of multiple biomarkers — are gaining traction, offering a more nuanced picture of tumor microenvironments and immune responses. Companion diagnostics are also becoming more prominent, helping identify patients most likely to benefit from specific immunotherapies. Interest in immune profiling as a personalized oncology strategy continues to climb, and biomarker-based approaches are increasingly embedded in clinical trial design. Demand is also rising for advanced assay platforms that streamline cancer research workflows and boost efficiency.
What immuno oncology assays actually do
These specialized laboratory tests evaluate how the immune system interacts with cancer. They measure biomarkers, immune cell function, cytokine levels, and gene expression related to tumors. For researchers and clinicians, they are essential tools for assessing the effectiveness of cancer immunotherapies, monitoring treatment outcomes, and identifying predictive biomarkers that inform personalized treatment plans.
The cancer burden connection
The growing number of cancer cases worldwide is a critical force behind the market’s expansion. Cancer prevalence — the number of individuals diagnosed with any cancer type within a population or time frame — is a key indicator of disease burden and healthcare demand. Risk factors like tobacco and alcohol use contribute significantly by exposing individuals to carcinogens that damage cells and raise mutation rates, particularly for cancers of the lung, liver, oral cavity, and esophagus. Immuno-oncology assays are pivotal in this context: they detect tumor-specific biomarkers, assess immune responses, support personalized immunotherapy choices, and track treatment success. Data from the Centers for Disease Control and Prevention, released in January 2026, underscores the scale of the challenge: the United States recorded approximately 1.85 million new cancer diagnoses in 2022, with cancer causing 613,349 deaths in 2023.
Regional leadership
North America held the largest share of the immuno oncology assays market in 2025, supported by advanced healthcare infrastructure and robust research activity. But the Asia-Pacific region is expected to be the fastest-growing market over the forecast period, fueled by rising healthcare investments and increasing cancer incidence. The report covers multiple regions — Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa — offering a broad view of global developments.
Our 2026 market reports now include enhanced strategic insights through:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As cancer rates climb and immunotherapy becomes a standard part of treatment, the assays used to guide those decisions are becoming indispensable. The sustained double-digit growth projected for this market signals that precision oncology is moving from aspiration to standard practice — and the tools that make it possible are only going to become more central to patient care.
